Slayback Rivals Xiromed On Taytulla – But With First CGT Designation
Eligible For 180 Days Of CGT Exclusivity
US-based player Slayback “will kick off a full commercial launch under its own label very soon” of the generic version of Allergan’s Taytulla for which it has just received approval with a competitive generic therapy designation.
